1,402.30
+0.25%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Haleos Labs
Its shares trade on NSE under the ticker HALEOSLABS.NS. It has been listed since 17 August 2017. In the fiscal year to 31 March 2026, it reported revenue of ₹3.34bn and net income of ₹173.1m. At that date it held total assets of ₹4.54bn and shareholders' equity of ₹2.14bn.
SMS Lifesciences India Ltd. engages in manufacturing and selling of active pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2017-08-17. The firm's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The firm's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The firm's wholly owned subsidiary is Mahi Drugs Private limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Aug 2017
- Employees
- 567
- Website
- smslife.in ↗
Leadership
Pay as last reported
- Mr. N. Rajendra PrasadChief Financial Officer, since 2020
- Mr. Trupti MohantyCompliance Officer, Company Secretary
- Shri. Veeravenkata TallurlManaging Director, Executive Director₹20.1m
- Mrs. Sudeepthl GoplneedlWhole-time Director, since 2021₹1.9m
- Mr. Talluri PraveenExecutive Director, since 2020₹7.2m
- Mr. P. Sarath KumarNon-Executive Independent Director₹600,000
- Dr. Mannam MalakondaiahNon-Executive Independent Director₹215,000
- Dr. Srinivas SamavedamNon-Executive Independent Director₹130,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Haleos Labs Ltd manufactures Ranitidine Hydrochloride USP / Ph.Eur / IP in Hyderabad with 567 employees.
- SMS Lifesciences India Ltd produces Famotidine USP / Ph.Eur / IP and Sildenafil Citrate USP / Ph.Eur / IP.
- The company's API products include Allopurinol USP / EP / IP and Ropivacaine Hydrochloride USP / EP / IP.
Weaknesses
- Haleos Labs Ltd has only two manufacturing facilities in Kazipally and Jeedimetla.
- The company's R&D center is located only in Sanath Nagar, Hyderabad.
- SMS Lifesciences India Ltd's subsidiary Mahi Drugs Private Limited is wholly owned.
Opportunities
- Haleos Labs Ltd can expand API production in Hyderabad with 567 employees.
- SMS Lifesciences India Ltd can leverage its API products like Brinzolamide and Tiagabine.
- The firm's manufacturing facilities at Kazipally and Jeedimetla offer potential for growth.
Threats
- Haleos Labs Ltd faces competition from other pharmaceutical companies in India.
- SMS Lifesciences India Ltd's API products may face regulatory challenges in global markets.
- The company's reliance on Hyderabad for manufacturing could pose supply chain risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.